Optimism at life sciences company as it celebrates record order book
ProBiotix Health, a life sciences business developing probiotics to support cardiometabolic health, reports its revenues climbed 13 per cent to £1.883m (2023: £1.673m) in its audited results for the period ended 31 December 2024.
The Wakefield-based company also recorded a pre-tax loss of £852,000 (2023: £762,000 pre-tax loss), adding that it has a solid financial position with cash balances totalling £1.65m (2023: £1.50m).
It also onboarded a record number of new customers and distributors.
Steen Andersen, CEO, said: “The current year has started strongly, with a record order book, significantly ahead of 2024.
“The robustness of the sales project pipeline has increased further with new product launches planned this year in North America and Europe.
“We feel confident about the continuing positive development of the company in 2025, enabling a move to reach break-even.
“We also continue to increase our commercial efforts within Europe, while keeping a strategic focus on key potential new markets.
“We look forward to building on the success of 2024 towards our strategic targets of £10m turnover in 2028 with £2m EBITDA and thank investors for their investment and continued belief in the management team.”
ProBiotix notes it believes its strong fundamentals are not yet fully reflected in its current market capitalisation.
The firm says comparisons with peer probiotic companies suggest “significant upside potential”, particularly as market conditions improve.
For more information and the source, visit: Optimism at life sciences company as it celebrates record order book | TheBusinessDesk.com